Literature DB >> 29998368

Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis.

Abhishek Zanwar1, Avinash Jain1, Latika Gupta1, Smirti Chaurasia1, Sandeep Kumar1, Durga Prasanna Misra1, Ramnath Misra2.   

Abstract

Despite many studies focused on involvement of T cell in pathogenesis of Takayasu arteritis (TaK), very few have explored the role of B cells. Hence, we sought evidence of B cell involvement in a large cohort of TaK by measuring serum levels of B cell survival factors activation factor (BAFF) and A proliferation inducing ligand (APRIL). Serum BAFF and APRIL levels were measured by ELISA in 50 patients and 48 healthy individuals, and further assessed for correlation with outcome measures, such as Indian Takayasu Clinical Activity Score-ESR (ITAS-ESR) and Takayasu arteritis Damage score (TADS). Forty women and ten men of median age 26 (11-52) and disease duration of 3 years (0.1-22) were studied. Type V disease was the most common subset (n = 31), while type I, II, III, and IV was seen in ten, four, three, and two patients respectively. Serum APRIL levels were raised in patients as compared to healthy controls [2087.5 pg/ml (1480.0-2279.0) vs. 1288.64 pg/ml, (844.2-1632.9) p = 0.01]. Median serum APRIL level was also raised in patients with active disease (n = 24) as compared to inactive disease (n = 26) 2098.79 pg/ml, (1930.75-2768.75) vs. 1802.5 pg/ml, (1066.75-2098); p = 0.03). Serum BAFF levels were not raised in patients with TaK when compared to healthy Individuals. Neither BAFF, nor APRIL levels correlated with disease activity (ITAS-ESR) or TADS. Elevated APRIL levels in active TaK suggest probable role of B cells in pathogenesis.

Entities:  

Keywords:  B cell; Indian Takayasu Clinical Activity Score; Large vessel vasculitis; Pathogenesis of Takayasu arteritis

Mesh:

Substances:

Year:  2018        PMID: 29998368     DOI: 10.1007/s10067-018-4207-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

Review 1.  [Role of anti-endothelial cell antibodies (AECA) in the development of Takayasu's arteritis].

Authors:  Joanna Kluz; Rajmund Adamiec
Journal:  Pol Arch Med Wewn       Date:  2004-02

2.  The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis.

Authors:  W P Arend; B A Michel; D A Bloch; G G Hunder; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

3.  Raised anticardiolipin antibodies in Takayasu's arteritis.

Authors:  R Misra; A Aggarwal; M Chag; N Sinha; S Shrivastava
Journal:  Lancet       Date:  1994-06-25       Impact factor: 79.321

Review 4.  B cell activating factor (BAFF) and BAFF receptors: fakes and facts.

Authors:  G Ferraccioli; E Gremese
Journal:  Clin Exp Immunol       Date:  2017-09-28       Impact factor: 4.330

5.  Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.

Authors:  S Phatak; S Chaurasia; S K Mishra; R Gupta; V Agrawal; A Aggarwal; R Misra
Journal:  Clin Exp Immunol       Date:  2016-12-05       Impact factor: 4.330

6.  Serum levels of BAFF for assessing the disease activity of Takayasu arteritis.

Authors:  Yuichiro Nishino; Mami Tamai; Atsushi Kawakami; Tomohiro Koga; Junya Makiyama; Yumi Maeda; Yuka Jiuchi; Taichiro Miyashita; Yasumori Izumi; Katsumi Eguchi; Kiyoshi Migita
Journal:  Clin Exp Rheumatol       Date:  2010 Jan-Feb       Impact factor: 4.473

Review 7.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

8.  Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010).

Authors:  Ramnath Misra; Debashish Danda; Sivakumar M Rajappa; Alakendu Ghosh; Rajiva Gupta; Kurugodu M Mahendranath; Lakshmanan Jeyaseelan; Able Lawrence; Paul A Bacon
Journal:  Rheumatology (Oxford)       Date:  2013-04-16       Impact factor: 7.580

9.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).

Authors:  Yoshikazu Nakaoka; Mitsuaki Isobe; Syuji Takei; Yoshiya Tanaka; Tomonori Ishii; Shumpei Yokota; Akira Nomura; Seitaro Yoshida; Norihiro Nishimoto
Journal:  Ann Rheum Dis       Date:  2017-11-30       Impact factor: 19.103

View more
  3 in total

Review 1.  Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.

Authors:  Enrico Tombetti; Elvis Hysa; Justin C Mason; Marco A Cimmino; Dario Camellino
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

2.  Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons.

Authors:  Kai Kang; Yue Sun; Yi Ling Li; Bing Chang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

Review 3.  Advances in Takayasu arteritis: An Asia Pacific perspective.

Authors:  Debashish Danda; Prathyusha Manikuppam; Xinping Tian; Masayoshi Harigai
Journal:  Front Med (Lausanne)       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.